B-cell activating factor receptor (BAFF-R) chimeric antigen receptor (CAR) T-cell therapy incited cytotoxic effects on both ...

Changes in the production of several immune proteins at the time of an ALS diagnosis were linked to disease progression in ...

Harnessing the body's B-cells to fight tumors may be a promising treatment for glioblastoma, according to a Northwestern ...

The introduction of clustered enhancing mutations led to complement activation by anti-capsule antibodies for both K.

Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...

University of Rochester researchers have demonstrated a noninvasive method using BL-OG, or bioluminescent optogenetics, that ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm ...

Antengene Corporation Limited (“ Antengene “, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

Proper storage and shipping conditions for cell and gene therapy products are crucial for the design, repeatability, and ...

Researchers identified a new mechanism in the DNA damage response involving the long non-coding RNA NEAT1. Increased NEAT1 ...

Researchers have developed a noninvasive method called bioluminescent optogenetics (BL-OG), which uses light to activate neurons in the brain without the need for implanted devices.

Casitas B-lineage lymphoma b (Cbl/b) is an E3 ubiquitin ligase that has been shown to be a key regulator of the activation of T and natural killer (NK) cells in the absence of CD28 costimulation GRC ...